Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial

JAMA

Volumn 292, Issue 11, 2004, Pages 1307-1316

  De Lemos, James A ^a   Blazing, Michael A ^b   Wiviott, Stephen D ^b   Lewis, Eldrin F ^b   Fox, Keith A A ^b   White, Harvey D ^b   Rouleau, Jean Lucien ^b   Pedersen, Terje R ^b   Gardner, Laura H ^b   Mukherjee, Robin ^b   Ramsey, Karen E ^b   Palmisano, Joanne ^b   Bilheimer, David W ^b   Pfeffer, Marc A ^b   Califf, Robert M ^b   Braunwald, Eugene ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

A TO Z TRIAL; ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CHRONOPHARMACOLOGY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DELAYED TREATMENT; DOUBLE BLIND PROCEDURE; DRUG DOSE INTENSITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EARLY TREATMENT; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; ANGINA PECTORIS; BLOOD; DRUG ADMINISTRATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

AGED; ANGINA PECTORIS; ANTILIPEMIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 4544243333     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.11.1307     Document Type: Article

References (17)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996:335:1001-1009.
3. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339: 1349-1357.
4. The Heart Protection Study Investigators. MRC/BHF Heart Protection Study of cholesterol lowering with Simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360: 7-22.
5. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
6. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495-1504.
7. Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. The A-to-Z Trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001;142:211-217.
8. Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA. 2004;292:55-64.
9. Davidson MH, Stein EA, Hunninghake DB, et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2000:10:253-262.
10. Kokko J. Rhabdomyolysis. In: Goldman L, Ausielo D, eds. Cecil's Textbook of Medicine 21st ed. Philadelphia, Pa: WB Saunders; 2000:522-526.
11. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Angina Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial nfarction. N Engl J Med. 1998; 338:1488-1497.
12. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004:291:1071-1080.
13. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
14. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes an observational study. Lancet 2001:357:1063-1068.
15. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001:285:430-436.
16. Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004:140:857-866.
17. Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndrome. JAMA. 2002:287:3087-3095.